Morgan Stanley’s CervoMed CRVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $39.4K | Sell |
12,699
-727,193
| -98% | -$2.56M | ﹤0.01% | 6591 |
|
|
2026
Q1 | $2.92M | Buy |
739,892
+265,398
| +56% | +$1.39M | ﹤0.01% | 4489 |
|
|
2025
Q4 | $3.75M | Buy |
474,494
+60,457
| +15% | +$486K | ﹤0.01% | 4396 |
|
|
2025
Q3 | $3.35M | Buy |
414,037
+38,747
| +10% | +$332K | ﹤0.01% | 4453 |
|
|
2025
Q2 | $2.36M | Buy |
375,290
+238,233
| +174% | +$2.03M | ﹤0.01% | 4594 |
|
|
2025
Q1 | $1.25M | Buy |
137,057
+86,429
| +171% | +$329K | ﹤0.01% | 4897 |
|
|
2024
Q4 | $118K | Buy |
50,628
+5,525
| +12% | +$53.7K | ﹤0.01% | 5991 |
|
|
2024
Q3 | $659K | Buy |
45,103
+37,436
| +488% | +$580K | ﹤0.01% | 5272 |
|
|
2024
Q2 | $131K | Buy |
7,667
+7,665
| +383,250% | +$168K | ﹤0.01% | 5863 |
|
|
2024
Q1 | $47 | Hold |
2
| – | – | ﹤0.01% | 7503 |
|
|
2023
Q4 | $15 | Sell |
2
-362
| -99% | -$3.13K | ﹤0.01% | 7734 |
|
|
2023
Q3 | $1.68K | Sell |
364
-1
| -0.3% | -$5 | ﹤0.01% | 7157 |
|
|
2023
Q2 | $1.83K | Hold |
365
| – | – | ﹤0.01% | 7210 |
|
|
2023
Q1 | $2.27K | Hold |
365
| – | – | ﹤0.01% | 7219 |
|
|
2022
Q4 | $2.77K | Hold |
365
| – | – | ﹤0.01% | 7293 |
|
|
2022
Q3 | $3K | Hold |
365
| – | – | ﹤0.01% | 7373 |
|
|
2022
Q2 | $4K | Hold |
365
| – | – | ﹤0.01% | 7442 |
|
|
2022
Q1 | $7K | Hold |
365
| – | – | ﹤0.01% | 7496 |
|
|
2021
Q4 | $8K | Buy |
365
+266
| +269% | +$8.32K | ﹤0.01% | 7526 |
|
|
2021
Q3 | $4K | Hold |
99
| – | – | ﹤0.01% | 7536 |
|
|
2021
Q2 | $5K | Sell |
99
-34
| -26% | -$1.88K | ﹤0.01% | 7372 |
|
|
2021
Q1 | $9K | Buy |
133
+120
| +923% | +$10.1K | ﹤0.01% | 6967 |
|
|
2020
Q4 | $1K | Buy |
+13
| New | +$761 | ﹤0.01% | 6940 |
|
|
2020
Q2 | – | Hold |
0
| – | – | – | 6617 |
|
|
2020
Q1 | – | Hold |
0
| – | – | – | 6582 |
|
|
2019
Q4 | – | Sell |
-13
| Closed | -$795 | – | 6664 |
|
|
2019
Q3 | $2K | Buy |
13
+10
| +333% | +$1.62K | ﹤0.01% | 6472 |
|
|
2019
Q2 | $1K | Buy |
+3
| New | +$809 | ﹤0.01% | 6527 |
|
|
2017
Q3 | – | Hold |
0
| – | – | – | 6541 |
|
|
2017
Q2 | – | Sell |
-11
| Closed | -$35.4K | – | 6595 |
|
|
2017
Q1 | $50K | Buy |
+11
| New | +$47.2K | ﹤0.01% | 5826 |
|
Other funds holding CRVO
SM
Morgan Stanley's CRVO Position: Q2 2026 in Review
Morgan Stanley reduced its CervoMed (CRVO) stake by 98% in Q2 2026, selling an estimated $2.56M and leaving 12,699 shares worth $39.4K. The position accounts for ﹤0.01% of the portfolio, ranked #6591.
Morgan Stanley first reported a position in CRVO in Q1 2017 and has held it in 26 quarters since. The position peaked at $3.75M in Q4 2025. 37 funds tracked by Wall St. Rank hold CRVO as of Q2 2026.
- Morgan Stanley held 12,699 shares of CervoMed worth $39.4K as of Q2 2026.
- Morgan Stanley sold 727,193 CervoMed shares in Q2 2026, an estimated $2.56M.
- CervoMed made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #6591 holding.
- Morgan Stanley first reported a position in CervoMed in Q1 2017 and has held it in 26 quarters since.
- Morgan Stanley's CervoMed position peaked at $3.75M in Q4 2025.
- 37 funds tracked by Wall St. Rank held CervoMed as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.